Vac­cine doc­u­ments, young lead­ers and mar­ket tur­moil: End­points' 10 biggest sto­ries of 2022

It’s been a volatile year in the world of bio­phar­ma. Mar­ket de­clines re­set M&A val­u­a­tions, and may be be­gin­ning to tempt big­ger buy­ers back in­to deal­mak­ing. Rus­sia’s war in Ukraine dis­rupt­ed drug sales and clin­i­cal tri­als. A new gen­er­a­tion of young biotech lead­ers emerged in the End­points 20(+1) Un­der 40. And as cap­i­tal runs dry in a tough en­vi­ron­ment for rais­ing new funds, com­pa­nies big and small are tak­ing a look at their head­counts and op­er­a­tions for ways to make it through lean times.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.